Trials / Unknown
UnknownNCT02562183
The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,186 (estimated)
- Sponsor
- Techpool Bio-Pharma Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
In order to reevaluate safety and efficacy of human urinary kallikrein in treating acute cerebral infarction ,a multi-center, open label , single group study was designed. Expect to enroll 60 sites and 2186 subjects. Subjects will receive kallikrein treatment according to real clinical practice (suggest above 14days treatment) and 90 days follow up
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | kallikrein | Using kallikrein |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2018-11-30
- Completion
- 2018-11-30
- First posted
- 2015-09-29
- Last updated
- 2018-01-17
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02562183. Inclusion in this directory is not an endorsement.